Print Page     Close Window     

SEC Filings

SERES THERAPEUTICS, INC. filed this Form S-3 on 03/16/2017
Entire Document

Table of Contents


Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Massachusetts, on the 16th day of March, 2017.


Seres Therapeutics, Inc.

/s/ Roger J. Pomerantz, M.D.


Roger J. Pomerantz

President, Chief Executive Officer and

Chairman of the Board


KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Roger J. Pomerantz, M.D. and Eric D. Shaff, or either of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to file and sign any and all amendments, including post-effective amendments and any registration statement for the same offering that is to be effective under Rule 462(b) of the Securities Act, to this registration statement, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes may lawfully do or cause to be done by virtue hereof. This power of attorney shall be governed by and construed with the laws of the State of Delaware and applicable federal securities laws.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.







/s/ Roger J. Pomerantz, M.D.

Roger J. Pomerantz, M.D.


President, Chief Executive Officer and Chairman of the Board

(Principal Executive Officer)

  March 16, 2017

/s/ Eric D. Shaff

Eric D. Shaff


Chief Financial Officer and Executive Vice President

(Principal Accounting Officer and Principal Financial Officer)

  March 16, 2017

/s/ Noubar B. Afeyan, Ph.D.

Noubar B. Afeyan, Ph.D.



  March 16, 2017

/s/ Dennis A. Ausiello, M.D.

Dennis A. Ausiello, M.D.



  March 16, 2017

/s/ Grégory Behar

Grégory Behar



  March 16, 2017

/s/ Kurt C. Graves

Kurt C. Graves



  March 16, 2017

© Seres Therapeutics. All Rights Reserved.